SCHEDULE 13G: Frazier Life Sciences Funds and Principals Report Significant Stake in Palvella Therapeutics, Exceeding 5% Ownership Threshold

A group of Frazier Life Sciences funds and their principals have filed a Schedule 13G, disclosing beneficial ownership of 5.1% of Palvella Therapeutics, Inc.'s Common Stock as of December 13, 2024.

Summary

• Frazier Life Sciences Public Fund, L.P. reported beneficial ownership of 440,575 shares, representing 3.9% of Palvella Therapeutics, Inc.'s Common Stock.
• Frazier Life Sciences Public Overage Fund, L.P. reported beneficial ownership of 129,905 shares, representing 1.2% of Palvella Therapeutics, Inc.'s Common Stock.
• Frazier Life Sciences X, L.P. reported beneficial ownership of 2,648 shares, representing 0.0% of Palvella Therapeutics, Inc.'s Common Stock.
• Frazier Life Sciences XI, L.P. reported beneficial ownership of 2,764 shares, representing 0.0% of Palvella Therapeutics, Inc.'s Common Stock.
• James N. Topper and Patrick J. Heron each reported shared beneficial ownership of 575,892 shares, equating to 5.1% of the class, through their roles in the general partners of the various Frazier Life Sciences funds.
• Albert Cha and James Brush each reported shared beneficial ownership of 570,480 shares, equating to 5.1% of the class, through their roles in the general partners of Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences Public Overage Fund, L.P.
• Daniel Estes reported shared beneficial ownership of 2,764 shares, equating to 0.0% of the class, through his role in the general partner of Frazier Life Sciences XI, L.P.
• The percentages are calculated based on 11,221,307 shares of Common Stock outstanding as of December 13, 2024, as reported by Palvella Therapeutics, Inc. in its Form 8-K filed on December 16, 2024.
• The filing group consists of multiple Frazier Life Sciences entities and key individuals, including James N. Topper, Patrick J. Heron, Albert Cha, James Brush, and Daniel Estes.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Palvella Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The sentiment is neutral to slightly positive, as a significant stake by a reputable investment group can be viewed favorably by the market, indicating confidence in the issuer.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a prominent life sciences-focused investment firm, Frazier Life Sciences, in Palvella Therapeutics, Inc. Such an investment by a specialized fund suggests a potential belief in the long-term prospects or specific pipeline assets of Palvella within the biotechnology and pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by a group of institutional investors and their principals may be viewed positively, potentially signaling confidence in the company's future and attracting further investor interest.
• Company Management: Awareness of a significant institutional shareholder group may influence strategic decisions, although the filing explicitly states the shares are not held for the purpose of changing or influencing control.

Key Dates

Keywords

Palvella Therapeutics, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Funds